Jan 2010 - Signum Biosciences has been awarded a $270K grant from the Alzheimer's Drug Discovery Foundation (ADDF) to investigate, "PP2A: A novel therapeutic target for Alzheimer's Disease". Signum Biosciences' news -ALZHEIMER’S DRUG DISCOVERY FOUNDATION's Press Release :
MARCH 31, 2010 – The Alzheimer’s Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $270,000 to Signum Biosciences, Inc. (Princeton, NJ) to evaluate small-molecule, orally delivered Protein Phosphatase 2a (PP2A)-modulatory compounds as disease-modifying therapeutics for Alzheimer’s disease.
Signum is developing lipid signal transduction modulators (STMs) for chronic neurodegenerative and inflammatory diseases. Signum’s STM technology, a promising new approach to Alzheimer’s, was licensed from the Princeton University Laboratory of Professor Jeffry Stock, a Signum cofounder and leader in signal transduction research. STMs activate PP2A, a master regulatory protein that, if compromised, can generate signaling imbalances leading to neuronal death and cognitive decline...[PDF] ALZHEIMER’S DRUG DISCOVERY FOUNDATION's Press Release -
